[P] [/B] Public consultation on draft revision 3 of Detailed guidance for the request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities, notification of substantial amendments and declaration of the end of the trial[/B] [/P] [P] The Clinical Trials Directive provides a regime of authorisation of the NCA, notification of substantial amendments, and declaration of the end of the trial, and exhaustively harmonises these aspects. The Commission is under an obligation to draw up detailed guidance to ensure that the format and content of the request for authorisation of a clinical trial are harmonised. A draft revision of the existing detailed guidance is being submitted for public consultation. Contributions should be sent by e-mail to [link]mailto:entr-pharmaceuticals@ec.europa.eu(entr-pharmaceuticals@ec.europa.eu)[/link]. [/P] [P] Deadline for public consultation: 8 September 2009.[/P]